ResVita Bio receives Rare Pediatric Disease Designation for RVB-001 as a Treatment for Netherton Syndrome - Press Release

BERKELEY, Calif., June 9, 2022 /PRNewswire/ -- ResVita Bio, a cellular therapies startup, announces that the FDA has granted Rare Pediatric Disease De

Related Keywords

Berkeley ,California ,United States ,Resvita Bio ,Amin Zargar , ,Rare Pediatric Disease Designation ,Netherton Syndrome ,Chief Executive Officer ,